Business
Bruker Announces Strategic Minority Investment in NovAliX
NovAliX is a drug discovery focused CRO with award-winning chemistry teams and one of the world’s most comprehensive biophysics platforms. Bruker and NovAliX
About this update from Bruker Corporation
[{"type":"text","content":"\n\nNovAliX is a drug discovery focused CRO with award-winning chemistry teams and one of the world’s most comprehensive biophysics platforms.\n\n\n\nBruker and NovAliX intend to collaborate on enabling new paradigms in drug discovery, leveraging advanced biophysical methods, and NMR in particular, to structural, binding and functional characterization.\n\n\n\n STRASBOURG, France--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) today announced a strategic investment in NovAliX, a preclinical Contract Research Organization (CRO) specializing in expert drug discovery services, headquartered in Strasbourg, France. The minority investment aims to accelerate the growth and further expansion of NovAliX, particularly within Europe and the United States.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807340165/en/NovAliX leadership team Stephan Jenn, Christophe Dubost, and Denis Zeyer (left to right)(Photo: Business Wire)\nBruker and NovAliX collaborate strategically to develop novel drug discovery technologies and methods, with the goal of enabling new paradigms in leveraging biophysical methods for drug discovery. The companies will partner on advancing functional structural biology, biophysical methods for characterizing molecular dynamics and interactions, biocondensates and aggregation, drug candidate binding, therapeutic mechanisms of action (MoA), and elucidating potential off-target effects.\n\n\nThe overarching objectives are to discover new or improved targets, as well as new drug modalities or optimized drug candidates, and to predict drug discovery failures earlier. NovAliX will benefit from Bruker’s unique technologies in innovative high-end biophysical characterization methods, particularly NMR, but also leveraging biosensors, mass spectrometry, single-cell and spatial biology tools, to advance NovAliX services for discovery and development of new medicines even faster.\n\n\nNovAliX excels in drug discovery, combining biophysics, medicinal chemistry, and pharmacology, and is home to award-winning scientists who have invented drugs that are benefiting patients today. Their advanced biophysics platform supports drug discovery from target assessment to lead optimization. NovAliX partnerships, e.g., with the Max Planck Institute in Cryo-EM, or on a unique...